Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Buy
69
SLNO Quote, Financials, Valuation and Earnings
Last price:
$52.26
Seasonality move
:
5.28%
Day range:
$36.00 - $40.08
52-week range:
$29.43 - $90.32
Dividend yield:
0%
P/E ratio:
177.24x
P/S ratio:
10.68x
P/B ratio:
4.53x
Volume:
3.6M
Avg. volume:
1.8M
1-year change:
-46.4%
Market cap:
$2.2B
Revenue:
$190.4M
EPS (TTM):
$0.22
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
SLNO
Soleno Therapeutics, Inc.
|
$93.8M | $0.08 | 246.95% | -- | $105.15 |
|
BSX
Boston Scientific Corp.
|
$5.2B | $0.79 | 9.79% | 62% | $100.81 |
|
ITGR
Integer Holdings Corp.
|
$426M | $1.19 | -2.33% | 88.24% | $93.25 |
|
MNKD
MannKind Corp.
|
$107.3M | $0.02 | 36.93% | -59.34% | $7.50 |
|
MOH
Molina Healthcare, Inc.
|
$10.9B | $2.38 | -3.68% | -60.91% | $150.65 |
|
NKTR
Nektar Therapeutics
|
$10.7M | -$1.79 | -6.46% | -30.91% | $128.13 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
SLNO
Soleno Therapeutics, Inc.
|
$39.49 | $105.15 | $2.2B | 177.24x | $0.00 | 0% | 10.68x |
|
BSX
Boston Scientific Corp.
|
$62.82 | $100.81 | $94.5B | 32.82x | $0.00 | 0% | 4.74x |
|
ITGR
Integer Holdings Corp.
|
$86.85 | $93.25 | $3B | 30.41x | $0.00 | 0% | 1.66x |
|
MNKD
MannKind Corp.
|
$2.50 | $7.50 | $753.6M | 145.59x | $0.00 | 0% | 2.19x |
|
MOH
Molina Healthcare, Inc.
|
$139.38 | $150.65 | $7.4B | 16.72x | $0.00 | 0% | 0.17x |
|
NKTR
Nektar Therapeutics
|
$76.99 | $128.13 | $1.4B | -- | $0.00 | 0% | 93.68x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
SLNO
Soleno Therapeutics, Inc.
|
10.46% | 1.531 | 2.17% | 5.44x |
|
BSX
Boston Scientific Corp.
|
33.07% | 1.671 | 8.45% | 0.94x |
|
ITGR
Integer Holdings Corp.
|
43% | -1.228 | 48.92% | 2.05x |
|
MNKD
MannKind Corp.
|
112.08% | 1.908 | 27.12% | 1.23x |
|
MOH
Molina Healthcare, Inc.
|
49.7% | 0.229 | 45.08% | 0.00x |
|
NKTR
Nektar Therapeutics
|
62.37% | 4.995 | 20.36% | 4.59x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
SLNO
Soleno Therapeutics, Inc.
|
$90.9M | $40.4M | 5.32% | 6.16% | 44.08% | $48.6M |
|
BSX
Boston Scientific Corp.
|
$3.6B | $1.2B | 8.3% | 12.55% | 22.93% | $1B |
|
ITGR
Integer Holdings Corp.
|
$106.1M | $51.1M | 3.47% | 6.11% | 10.86% | $27.9M |
|
MNKD
MannKind Corp.
|
$78.3M | -$1.7M | 3.35% | -- | -1.49% | -$9.4M |
|
MOH
Molina Healthcare, Inc.
|
-- | -$162M | 5.89% | 10.89% | -1.88% | -$297M |
|
NKTR
Nektar Therapeutics
|
$21.6M | -$19.1M | -74.66% | -364.32% | -87.54% | -$65M |
Soleno Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns SLNO or BSX?
Boston Scientific Corp. has a net margin of 46.82% compared to Soleno Therapeutics, Inc.'s net margin of 12.68%. Soleno Therapeutics, Inc.'s return on equity of 6.16% beat Boston Scientific Corp.'s return on equity of 12.55%.
Company Gross Margin Earnings Per Share Invested Capital SLNOSoleno Therapeutics, Inc.99.06% $0.79 $502.7M BSXBoston Scientific Corp.68.5% $0.45 $36.4B -
What do Analysts Say About SLNO or BSX?
Soleno Therapeutics, Inc. has a consensus price target of $105.15, signalling upside risk potential of 166.28%. On the other hand Boston Scientific Corp. has an analysts' consensus of $100.81 which suggests that it could grow by 60.48%. Given that Soleno Therapeutics, Inc. has higher upside potential than Boston Scientific Corp., analysts believe Soleno Therapeutics, Inc. is more attractive than Boston Scientific Corp..
Company Buy Ratings Hold Ratings Sell Ratings SLNOSoleno Therapeutics, Inc.10 0 0 BSXBoston Scientific Corp.24 0 0 -
Is SLNO or BSX More Risky?
Soleno Therapeutics, Inc. has a beta of -2.804, which suggesting that the stock is 380.385% less volatile than S&P 500. In comparison Boston Scientific Corp. has a beta of 0.781, suggesting its less volatile than the S&P 500 by 21.926%.
-
Which is a Better Dividend Stock SLNO or BSX?
Soleno Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Boston Scientific Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Soleno Therapeutics, Inc. pays -- of its earnings as a dividend. Boston Scientific Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SLNO or BSX?
Soleno Therapeutics, Inc. quarterly revenues are $91.7M, which are smaller than Boston Scientific Corp. quarterly revenues of $5.3B. Soleno Therapeutics, Inc.'s net income of $42.9M is lower than Boston Scientific Corp.'s net income of $670M. Notably, Soleno Therapeutics, Inc.'s price-to-earnings ratio is 177.24x while Boston Scientific Corp.'s PE ratio is 32.82x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Soleno Therapeutics, Inc. is 10.68x versus 4.74x for Boston Scientific Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SLNOSoleno Therapeutics, Inc.10.68x 177.24x $91.7M $42.9M BSXBoston Scientific Corp.4.74x 32.82x $5.3B $670M
-
Which has Higher Returns SLNO or ITGR?
Integer Holdings Corp. has a net margin of 46.82% compared to Soleno Therapeutics, Inc.'s net margin of 10.32%. Soleno Therapeutics, Inc.'s return on equity of 6.16% beat Integer Holdings Corp.'s return on equity of 6.11%.
Company Gross Margin Earnings Per Share Invested Capital SLNOSoleno Therapeutics, Inc.99.06% $0.79 $502.7M ITGRInteger Holdings Corp.22.53% $1.38 $3.1B -
What do Analysts Say About SLNO or ITGR?
Soleno Therapeutics, Inc. has a consensus price target of $105.15, signalling upside risk potential of 166.28%. On the other hand Integer Holdings Corp. has an analysts' consensus of $93.25 which suggests that it could grow by 7.37%. Given that Soleno Therapeutics, Inc. has higher upside potential than Integer Holdings Corp., analysts believe Soleno Therapeutics, Inc. is more attractive than Integer Holdings Corp..
Company Buy Ratings Hold Ratings Sell Ratings SLNOSoleno Therapeutics, Inc.10 0 0 ITGRInteger Holdings Corp.3 5 0 -
Is SLNO or ITGR More Risky?
Soleno Therapeutics, Inc. has a beta of -2.804, which suggesting that the stock is 380.385% less volatile than S&P 500. In comparison Integer Holdings Corp. has a beta of 0.710, suggesting its less volatile than the S&P 500 by 28.956%.
-
Which is a Better Dividend Stock SLNO or ITGR?
Soleno Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Integer Holdings Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Soleno Therapeutics, Inc. pays -- of its earnings as a dividend. Integer Holdings Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SLNO or ITGR?
Soleno Therapeutics, Inc. quarterly revenues are $91.7M, which are smaller than Integer Holdings Corp. quarterly revenues of $470.9M. Soleno Therapeutics, Inc.'s net income of $42.9M is lower than Integer Holdings Corp.'s net income of $48.6M. Notably, Soleno Therapeutics, Inc.'s price-to-earnings ratio is 177.24x while Integer Holdings Corp.'s PE ratio is 30.41x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Soleno Therapeutics, Inc. is 10.68x versus 1.66x for Integer Holdings Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SLNOSoleno Therapeutics, Inc.10.68x 177.24x $91.7M $42.9M ITGRInteger Holdings Corp.1.66x 30.41x $470.9M $48.6M
-
Which has Higher Returns SLNO or MNKD?
MannKind Corp. has a net margin of 46.82% compared to Soleno Therapeutics, Inc.'s net margin of -14.25%. Soleno Therapeutics, Inc.'s return on equity of 6.16% beat MannKind Corp.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SLNOSoleno Therapeutics, Inc.99.06% $0.79 $502.7M MNKDMannKind Corp.69.95% -$0.05 $422.4M -
What do Analysts Say About SLNO or MNKD?
Soleno Therapeutics, Inc. has a consensus price target of $105.15, signalling upside risk potential of 166.28%. On the other hand MannKind Corp. has an analysts' consensus of $7.50 which suggests that it could grow by 200%. Given that MannKind Corp. has higher upside potential than Soleno Therapeutics, Inc., analysts believe MannKind Corp. is more attractive than Soleno Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SLNOSoleno Therapeutics, Inc.10 0 0 MNKDMannKind Corp.8 1 0 -
Is SLNO or MNKD More Risky?
Soleno Therapeutics, Inc. has a beta of -2.804, which suggesting that the stock is 380.385% less volatile than S&P 500. In comparison MannKind Corp. has a beta of 1.042, suggesting its more volatile than the S&P 500 by 4.225%.
-
Which is a Better Dividend Stock SLNO or MNKD?
Soleno Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. MannKind Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Soleno Therapeutics, Inc. pays -- of its earnings as a dividend. MannKind Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SLNO or MNKD?
Soleno Therapeutics, Inc. quarterly revenues are $91.7M, which are smaller than MannKind Corp. quarterly revenues of $112M. Soleno Therapeutics, Inc.'s net income of $42.9M is higher than MannKind Corp.'s net income of -$15.9M. Notably, Soleno Therapeutics, Inc.'s price-to-earnings ratio is 177.24x while MannKind Corp.'s PE ratio is 145.59x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Soleno Therapeutics, Inc. is 10.68x versus 2.19x for MannKind Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SLNOSoleno Therapeutics, Inc.10.68x 177.24x $91.7M $42.9M MNKDMannKind Corp.2.19x 145.59x $112M -$15.9M
-
Which has Higher Returns SLNO or MOH?
Molina Healthcare, Inc. has a net margin of 46.82% compared to Soleno Therapeutics, Inc.'s net margin of -1.41%. Soleno Therapeutics, Inc.'s return on equity of 6.16% beat Molina Healthcare, Inc.'s return on equity of 10.89%.
Company Gross Margin Earnings Per Share Invested Capital SLNOSoleno Therapeutics, Inc.99.06% $0.79 $502.7M MOHMolina Healthcare, Inc.-- -$3.14 $8.1B -
What do Analysts Say About SLNO or MOH?
Soleno Therapeutics, Inc. has a consensus price target of $105.15, signalling upside risk potential of 166.28%. On the other hand Molina Healthcare, Inc. has an analysts' consensus of $150.65 which suggests that it could grow by 7.08%. Given that Soleno Therapeutics, Inc. has higher upside potential than Molina Healthcare, Inc., analysts believe Soleno Therapeutics, Inc. is more attractive than Molina Healthcare, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SLNOSoleno Therapeutics, Inc.10 0 0 MOHMolina Healthcare, Inc.3 13 0 -
Is SLNO or MOH More Risky?
Soleno Therapeutics, Inc. has a beta of -2.804, which suggesting that the stock is 380.385% less volatile than S&P 500. In comparison Molina Healthcare, Inc. has a beta of 0.554, suggesting its less volatile than the S&P 500 by 44.602%.
-
Which is a Better Dividend Stock SLNO or MOH?
Soleno Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Molina Healthcare, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Soleno Therapeutics, Inc. pays -- of its earnings as a dividend. Molina Healthcare, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SLNO or MOH?
Soleno Therapeutics, Inc. quarterly revenues are $91.7M, which are smaller than Molina Healthcare, Inc. quarterly revenues of $11.4B. Soleno Therapeutics, Inc.'s net income of $42.9M is higher than Molina Healthcare, Inc.'s net income of -$160M. Notably, Soleno Therapeutics, Inc.'s price-to-earnings ratio is 177.24x while Molina Healthcare, Inc.'s PE ratio is 16.72x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Soleno Therapeutics, Inc. is 10.68x versus 0.17x for Molina Healthcare, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SLNOSoleno Therapeutics, Inc.10.68x 177.24x $91.7M $42.9M MOHMolina Healthcare, Inc.0.17x 16.72x $11.4B -$160M
-
Which has Higher Returns SLNO or NKTR?
Nektar Therapeutics has a net margin of 46.82% compared to Soleno Therapeutics, Inc.'s net margin of -165.45%. Soleno Therapeutics, Inc.'s return on equity of 6.16% beat Nektar Therapeutics's return on equity of -364.32%.
Company Gross Margin Earnings Per Share Invested Capital SLNOSoleno Therapeutics, Inc.99.06% $0.79 $502.7M NKTRNektar Therapeutics99.13% -$1.78 $238.7M -
What do Analysts Say About SLNO or NKTR?
Soleno Therapeutics, Inc. has a consensus price target of $105.15, signalling upside risk potential of 166.28%. On the other hand Nektar Therapeutics has an analysts' consensus of $128.13 which suggests that it could grow by 66.42%. Given that Soleno Therapeutics, Inc. has higher upside potential than Nektar Therapeutics, analysts believe Soleno Therapeutics, Inc. is more attractive than Nektar Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings SLNOSoleno Therapeutics, Inc.10 0 0 NKTRNektar Therapeutics8 1 0 -
Is SLNO or NKTR More Risky?
Soleno Therapeutics, Inc. has a beta of -2.804, which suggesting that the stock is 380.385% less volatile than S&P 500. In comparison Nektar Therapeutics has a beta of 1.165, suggesting its more volatile than the S&P 500 by 16.45%.
-
Which is a Better Dividend Stock SLNO or NKTR?
Soleno Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nektar Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Soleno Therapeutics, Inc. pays -- of its earnings as a dividend. Nektar Therapeutics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SLNO or NKTR?
Soleno Therapeutics, Inc. quarterly revenues are $91.7M, which are larger than Nektar Therapeutics quarterly revenues of $21.8M. Soleno Therapeutics, Inc.'s net income of $42.9M is higher than Nektar Therapeutics's net income of -$36.1M. Notably, Soleno Therapeutics, Inc.'s price-to-earnings ratio is 177.24x while Nektar Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Soleno Therapeutics, Inc. is 10.68x versus 93.68x for Nektar Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SLNOSoleno Therapeutics, Inc.10.68x 177.24x $91.7M $42.9M NKTRNektar Therapeutics93.68x -- $21.8M -$36.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
46
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 36x
Sell
49
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 34x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 27x
Alerts
Buy
69
SLNO alert for Apr 6
Soleno Therapeutics, Inc. [SLNO] is up 32.34% over the past day.
Buy
64
AEHR alert for Apr 6
Aehr Test Systems [AEHR] is up 17.87% over the past day.
Buy
77
CAR alert for Apr 6
Avis Budget Group, Inc. [CAR] is up 11.73% over the past day.
